InsiderTrades

Form 4 for PRLD Prelude Therapeutics Inc

Accepted 2024-10-07 00:00:00 ET · period of report 2024-10-04 · accession 0001562180-24-007253 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-10-07 2024-10-04 PRLD Huang Jane Pres, CMO F - Tax $2.00 -3,349 63.3K -5% -$6,698
D 2024-10-07 2024-10-04 PRLD Huang Jane Pres, CMO M - OptEx — +9,375 66.7K +16% —
D 2024-10-07 2024-10-04 PRLD Huang Jane Pres, CMO M - OptEx $0.00 -9,375 56.2K -14% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-10-04 F D 3,349 $2.00 63,341 D — — (F2) Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs.
2 Common Common Stock 2024-10-04 M A 9,375 — 66,690 D — — (F1) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock.
3 Derivative Restricted Stock Unit 2024-10-04 M D 9,375 $0.00 56,250 D — · — to — 9,375 Common Stock (F1) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. (F3) The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date.